CD274 and neoplasm: The primary analysis population in the JAVELIN Lung 100 study consists of patients with high PD-L1-expressing tumors (≥80% of tumor cells; 73-10 assay); hence, this study will provide an assessment of avelumab in a patient population similar to those of earlier trials of anti-PD-1/PD-L1 monotherapy.